Sort   by:  
 Page size 
GenomicsTrametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
PRJNA989582 | ENA
GenomicsExtracellular Nicotinamide Phosphoribosyltransferase neutralisation harnesses T cell responses in breast cancer by repressing the PD-1/PD-L1 axis
Extracellular Nicotinamide Phosphoribosyltransferase neutralisation harnesses T cell responses in breast cancer by repressing the PD-1/PD-L1 axis
PRJNA926664 | ENA
UnknownPD-L1/PD-1 Axis in Glioblastoma Multiforme.
Not available
S-EPMC6862444 | biostudies-literature
GenomicsPD-L1 positive astrocytes attenuate inflammatory functions of PD 1 positive microglia in models of autoimmune neuroinflammation [RNA-seq: IFNb]
PD-L1 positive astrocytes attenuate inflammatory functions of PD 1 positive microglia in models of autoimmune neuroinflammation [RNA-seq: IFNb]
PRJNA1001314 | ENA
GenomicsPD-L1 positive astrocytes attenuate inflammatory functions of PD 1 positive microglia in models of autoimmune neuroinflammation [RNA-seq: BMS202]
PD-L1 positive astrocytes attenuate inflammatory functions of PD 1 positive microglia in models of autoimmune neuroinflammation [RNA-seq: BMS202]
PRJNA1001312 | ENA
UnknownThe PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer.
Not available
S-EPMC8232689 | biostudies-literature
MetabolomicsCeramide Disrupts TM9SF2-PGK1 Axis to Redirect PD-L1 Trafficking and Enhance Antitumor Immunity

The PD-1/PD-L1 axis represents a cornerstone of cancer immunotherapy, yet the dynamic shuttling of PD-L1 between endosomal recycling and lysosomal degradation routes limits durable responses. Using a CRISPR screen targeting glycosphingolipid metabolism, we identify TM9SF2 as a key regulator of PD...

2026-02-05 | MTBLS13838 | MetaboLights
ProteomicsCeramide Disrupts TM9SF2-PGK1 Axis to Redirect PD-L1 Trafficking and Enhance Antitumor Immunity
The programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) axis represents a cornerstone of cancer immunotherapy, yet the dynamic shuttling of PD-L1 between endosomal recycling and lysosomal degradation routes limits durable responses. Using a CRISPR screen targeting glycosphingo...
ORGANISM(S): Homo Sapiens 
2026-02-27 | PXD075012 |
GenomicsPD-1-PD-L1 Axis Activation Suppresses CD8+ T Cells and Improves Nephritis.
PD-1-PD-L1 Axis Activation Suppresses CD8+ T Cells and Improves Nephritis.
PRJNA951663 | ENA
UnknownPeptide-based inhibitors targeting the PD-1/PD-L1 axis: potential immunotherapeutics for cancer.
Not available
S-EPMC10877416 | biostudies-literature
Sort   by:  
 Page size